This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Elanco offers anti-parasitic drug divestment to allay Australian concerns over Bayer deal

By Laurel Henning ( May 29, 2020, 03:56 GMT | Insight) -- US-based Elanco Animal Health has proposed to divest some of its animal-health products, in a bid to clear an informal Australian review of its plans to acquire the animal-health business of German pharmaceutical company Bayer. The divestment proposals respond to two areas of concern for the Australian Competition & Consumer Commission in its preliminary assessment of the $7.6 billion merger: the consolidation of worming treatments for cats and dogs, as well as sheep-lice products. US-based Elanco Animal Health has proposed to divest some of its animal-health products, in a bid to clear an informal Australian review of its plans to acquire the animal-health business of German pharmaceutical company Bayer....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login